Robotic-assisted radical prostatectomy in 2010. Issue 5 (May 2010)

• Record Type: Journal Article
• Authors: Singh, Iqbal; Hemal, Ashok K
• Is Part Of: Expert review of anticancer therapy. Volume 10:Issue 5(2010)
• Page Start: 671
• Page End: 682
• Publication Date: 2010-05
• Subjects: cancer control -- functional outcomes -- laparoscopic radical prostatectomy -- laparoscopy -- prostate cancer -- prostatectomy -- radical prostatectomy -- robotic -- robotic-assisted radical prostatectomy; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/era.10.35
• Languages: English
• ISSNs: 1473-7140

Abstract

This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were then reviewed, summarized and analyzed for their salient features. A literature search yielded 19 major publications on RARP in the preceding 2 years. A review of the current RARP literature (2006––2009) of multi-institutional cases of RARP demonstrated a mean operating room time, blood loss, hospital stay, positive surgical margin rate and perioperative-complication rate of approximately 194 min, 196 ml, 1.43 days, 25.7% and 5.83 %, respectively (based on the analysis of data using central tendency measures [mean]). The overall potency and continence rates were 73.6 and 87.1%, respectively (based on analysis of the published and reported data). All RARP cases were performed with the use of da Vinci robotic system ®® (Intuitive Surgical, CA, USA). It is expected that in 2010 close to 70% of radical prostatectomies in the USA will be performed with robotic assistance. The patient and surgeon appeal for RARP continues to expand exponentially. It seems pertinent to conclude that increasing experience with RARP may reduce the incidence of positive surgical margins and will improve the functional outcome, which is the challenge at this point in time. Although the early cancer control and intermediate follow-up on functional outcome with RARP appears to be convincing and favorable, the long-term (∼∼10 years) data are still awaited.